Even thought it was really tight lipped with the last trial, every time the stock moved it was presumed that someone must know something and it kind of feeds on itself. This go around there should be 3 times the patients showing benefit so you never know. Also last go around Alkon and the former CEO did mention that there had been improvements and the safety of the drug as anecdotal evidence of course at the investor presentations. We should have seen at least the first few dosed patients completely finish the study likely within the last week including the final follow up. Exciting times for those involved even though we'll have to be patient for the results to come in.
News 
Market Data 
Discover 
